• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

News

Virpax begins pre-clinical studies of intranasal enkephalin to support IND

Virpax Pharmaceuticals said that the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health has begun pre-clinical studies of Virpax's Envelta intranasal enkephalin to support an IND submission. Virpax signed a cooperative research and development agreement with NCATS in August 2020. Envelta is delivered via a single use … [Read more...] about Virpax begins pre-clinical studies of intranasal enkephalin to support IND

Aridis announces planned clinical development of inhaled mAb cocktail for COVID-19

Aridis Pharmaceuticals announced that it is now receiving preclinical support from the NIAID (National Institute of Allergy and Infectious Diseases) and CoVIC (Coronavirus Immunotherapy Consortium) for a nebulized monoclonal antibody cocktail for COVID-19 and that it plans to initiate a Phase 1/2/3 clinical trial in the second half of this year. The company also said … [Read more...] about Aridis announces planned clinical development of inhaled mAb cocktail for COVID-19

Clinical trial of intranasal niclosamide for the prevention of COVID-19 gets underway

According to Union therapeutics, the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge have begun recruiting kidney patients for a clinical trial of Union's UNI91103 intranasal niclosamide for the prevention of COVID-19 in vulnerable patients. The PROTECT-V (PROphylaxis for vulnerable paTiEnts at risk of COVID-19 infecTion) trial is … [Read more...] about Clinical trial of intranasal niclosamide for the prevention of COVID-19 gets underway

Ryaltris nasal spray approved by Russian Ministry of Health

Glenmark Pharmaceuticals announced that the Ministry of Health of the Russian Federation  has approved Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal and perennial allergic rhinitis, and the company expects to launch the nasal spray in Russia in the first quarter of fiscal year 2021-22.  Glenmark Pharmaceuticals Senior … [Read more...] about Ryaltris nasal spray approved by Russian Ministry of Health

Microbion gets additional funding from CFF for inhaled pravibismane

According to Microbion Corporation, the company has received up to $1.8 million from the Cystic Fibrosis Foundation to fund toxicology studies to support an IND for the company's pravibismane inhalation suspension for the treatment of lung infections in CF patients. CFF had previously provided a grant worth up to $5.6 million for development of the inhaled … [Read more...] about Microbion gets additional funding from CFF for inhaled pravibismane

TFF Pharmaceuticals says it has formulated a dry powder mAb against Ebola and vaccine against equine encephalitis

TFF Pharmaceuticals said that in vitro testing has confirmed the efficacy of a monoclonal antibody against Ebolavirus Zaire and a recombinant vesicular stomatitis virus (rVSV) vaccine candidate against Venezuelan equine encephalitis virus formulated using the company's thin film freezing technology. According to TFF, the in vitro studies demonstrated that both the … [Read more...] about TFF Pharmaceuticals says it has formulated a dry powder mAb against Ebola and vaccine against equine encephalitis

Insmed says Phase 1 study of treprostinil palmitil inhalation powder supports once-daily dosing

Insmed Incorporated has announced data from a Phase 1 study of its treprostinil palmitil inhalation powder (TPIP) in healthy volunteers demonstrated that TPIP was generally safe and well tolerated and had a lower Cmax and longer half-life than Tyvaso. The study enrolled 42 subjects and evaluated doses as high as 225 µg for a repeated dose and 675 µg for a single … [Read more...] about Insmed says Phase 1 study of treprostinil palmitil inhalation powder supports once-daily dosing

Seelos repurchases royalties on any future sales of SLS-002 intranasal racemic ketamine

Seelos Therapeuticse has announced an additional amendment to its 2018 agreement with Vyera Pharmaceuticals (now Phoenixus) in order for the company to repurchase 9% of royalties payable on any future net sales of SLS-002 intranasal racemic ketamine. A previous amendment to the agreement that allowed Seelos to make cash and stock payments instead of a milestone … [Read more...] about Seelos repurchases royalties on any future sales of SLS-002 intranasal racemic ketamine

CEBINA partners with Ursapharm Arzneimittel to develop azelastine nasal spray for the treatment of COVID-19

The Central European Biotech Incubator and Accelerator (CEBINA) has announced a partnership with Ursapharm Arzneimittel to repurpose Ursapharm's Pollival azelastine nasal spray for the treatment of COVID-19. In July 2020, CEBINA announced that it had filed a patent application for the use of azelastine to treat COVID-19 and that it was looking for partners … [Read more...] about CEBINA partners with Ursapharm Arzneimittel to develop azelastine nasal spray for the treatment of COVID-19

FDA clears Altimmune’s IND for AdCOVID intranasal vaccine

According to Altimmune, the FDA has now cleared the company’s IND for a Phase 1 trial of its AdCOVID intranasal vaccine candidate, and enrollment in the trial is expected to begin within a week. Altimmune initially submitted the IND in November 2020, and the FDA placed a clinical hold on the application in December 2020 citing the need for changes to the protocols … [Read more...] about FDA clears Altimmune’s IND for AdCOVID intranasal vaccine

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 118
  • Page 119
  • Page 120
  • Page 121
  • Page 122
  • Interim pages omitted …
  • Page 417
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews